Paul Tudor Jones Mersana Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $193,094 - $339,955	-67,991 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $254,286 - $450,780	67,991 New	67,991 $271,000
Q3 2021 Nov 15, 2021	SELL	$8.56 - $14.47 $89,443 - $151,197	-10,449 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $138,762 - $188,813	10,449 New	10,449 $142,000
Q4 2017 Feb 14, 2018	SELL	$14.95 - $19.9 $299,000 - $398,000	-20,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$14.8 - $18.06 $296,000 - $361,200	20,000	20,000 $346,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $155M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.